Researchers have discovered how Mycoplasma pneumoniae obtains essential lipids from the human body and targets fat-rich tissues. The bacterium uses the P116 protein to capture cholesterol and other lipids, allowing it to survive and colonize tissues beyond the lungs.
Scientists have uncovered the molecular structure of Mycoplasma mobile's twin motors that power its gliding ability, using cryo-electron microscopy. The complex structure reveals a new mechanism by which energy from ATP hydrolysis is converted into motility.
A new study has identified novel strains of microbes that have adapted to use limited resources in cities, including those found in Hong Kong's subways and skin. These microbes can metabolize manufactured products, posing health risks if they are pathogenic.
Researchers discovered Mycoplasma pneumoniae's lipids spur T cells to overproduce IL-17, leading to neutrophil recruitment and vaccine-enhanced disease. B cells also play a role in modulating the immune response, suggesting they may hold disease in check.
Researchers observe atomic-level structural changes in bacterial ribosomes and their response to antibiotics, shedding light on mechanisms of action and potential off-target effects. The study provides new insights into the complex interactions between ribosomes and other cellular complexes.
Researchers captured the internal motor structure of Mycoplasma mobile, revealing an internal chain structure causing the external appendage structure to move in a specific direction. The study provides insight into the gliding motion mechanism and could lead to understanding human replications of it.
A team of veterinarians from RUDN University tested a complex preparation called gentaminoseleferon to treat respiratory infection in calves. The study showed that the treatment reduced inflammatory processes and promoted active recovery of metabolism, indicating its therapeutic efficiency.
Researchers at Linköping University discover that bacteria, not human cells, are responsible for the detection of epigenetic mark 6mdA. The team finds multiple methods used to detect 6mdA produce false positive results due to bacterial contamination and technical issues.
Researchers discovered specific immune cells called B cells play a crucial role in eliminating mycoplasma bacteria from the lungs. Vaccines may be developed to elicit antibody responses protecting against infection, offering an alternative to antibiotics.
Researchers discovered that Mycoplasma agalactiae uses a molecular stealth mechanism to evade the immune system. The bacteria can compensate for gene inactivation through an alternative mechanism, allowing them to survive and persist in infected hosts.
Researchers created a three-dimensional map of Mycoplasma pneumoniae's circular chromosome, revealing a previously unknown layer of gene regulation. The study found that the tiny bacterium's genome is organised into distinct structural domains, each containing genes turned on or off in a coordinated way.
Researchers have identified Mycoplasma pneumoniae as the trigger for Guillain-Barré syndrome, a serious nervous system disease. The study found that antibodies against the bacteria's surface structure react with human nerve sheaths, leading to an immune reaction and potentially life-threatening paralysis.
Researchers found Mycoplasma pneumoniae infections in over half of hospitalized children with pneumonia in Beijing, predicting an ongoing epidemic. The study may help clinicians slow the spread of the disease.
The EU-funded MycoSynVac project combines gene engineering and biotechnology to design a novel veterinary vaccine chassis based on Mycoplasma pneumoniae. This chassis will be used to create specific vaccines against two highly detrimental pathogens, as well as for cell therapy and infectious lung disease treatment.
The molecular structure of the cytotoxin from Mycoplasma pneumoniae has been determined, which could lead to the development of effective drugs and vaccines to neutralize its injurious effects. The discovery is a significant breakthrough in understanding respiratory infections such as asthma.
Scientists have identified three proteins - GapA, CrmA and Mgc2 - essential for the gliding mechanism of Mycoplasma gallisepticum. This discovery could lead to developing a vaccine by targeting non-motile, non-pathogenic bacteria.
A devastating bird disease caused by Mycoplasma gallisepticum has spread rapidly across North America, with the bacteria evolving at a faster rate than previously estimated. The microbe has lost over 50 genes, including those that make up its immune system, since making the switch to its new host.
Researchers at Vetmeduni Vienna identified a novel mechanism by which Mycoplasma agalactiae switches its surface protein genes. The so-called phase variation is caused by alterations in short DNA sequences controlled by an enzyme called recombinase. This process enables the organism to avoid host defense mechanisms during infection.
A study published in the American Journal of Obstetrics & Gynecology found that 23% of neonates born between 23 and 32 weeks gestation have positive umbilical blood cultures for genital mycoplasmas, a frequent cause of congenital fetal infection. These infections are associated with increased risk of neonatal systemic inflammatory resp...
A recent study suggests that mycoplasma bacterial infections may cause or exacerbate asthma attacks in children. The research found that nearly half of children experiencing their first asthma attack were infected with mycoplasma. Testing for mycoplasma infection in asthmatic children could help prevent future attacks.